Hebei Senlang Biotechnology Company
Hebei Senlang Biotechnology is focused on the treatment of immune cells new technology development and application of high-tech enterprises.
Technology:
CAR-T therapy
Industry:
Private
Headquarters:
Dongguan, Hebei, China
Founded Date:
2016-01-01
Funding Status:
Private Equity
Investors Number:
3
Total Funding:
200000000
Estimated Revenue:
$10M to $50M
Last Funding Date:
2022-05-18
Last Funding Type:
Private Equity
Register and Claim Ownership